VirotherapyThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3

131 records returned

Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer modelEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Breast cancer is the second leading cause of malignant effusions in cancer patients. Pleural effusion indicates incurable disease with limited palliative treatment options and poor outcome. Here, we demonstrate the therapeutic efficacy of measles virus (MV) vaccine strain derivative against malignant pleural effusion in an MDA-MB-231 xenograft model of advanced breast cancer. Both systemic intravenous (i.v.) and intrapleural (t.t.) administered virus caused massive infection and syncytia formation in the pleural tumor deposits. Intrapleural administration of 1.5 × 106 plaque-forming units...
Source: Breast Cancer Research and Treatment - November 5, 2009 Category: Cancer & Oncology Tags: Breast Cancer Research and Treatment Source Type: journals

Targeting a Mimotope Vaccine to Activating Fc{gamma} Receptors Empowers Dendritic Cells to Prime Specific CD8+ T Cell Responses in Tumor-Bearing Mice.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A major challenge for inducing antitumor immune responses with native or modified tumor/self-Ags in tumor-bearing hosts relates to achieving efficient uptake and processing by dendritic cells (DCs) to activate immune effector cells and limit the generation of regulatory T cell activity. We analyzed the ability of therapeutic DC vaccines expressing a CD166 cross-reactive mimotope of the GD2 ganglioside, 47-LDA, to selectively expand adoptively transferred, tumor-specific T cells in NXS2 neuroblastoma tumor-bearing syngeneic mice. Before the adoptive cell transfer and DC vaccination, the tumor-bearing mice were lymphodep...
Source: Journal of Immunology - October 20, 2009 Category: Allergy & Immunology Authors: Gil M, Bieniasz M, Wierzbicki A, Bambach BJ, Rokita H, Kozbor D Tags: J Immunol Source Type: journals

Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent virusesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Summary: Oncolytic virotherapy utilizes viruses that can selectively destroy cancer cells without harming normal tissues. Clinical trials of oncolytic viruses show that most oncolytic agents are well tolerated and safe. The virotherapeutic agents currently in use have limited potency when administered alone; however, combination therapy using virotherapeutic agents and conventional anticancer agents, such as chemotherapeutics, radiation, and gene therapy, exhibits encouraging levels of efficacy. Advances in recombinant DNA technology have allowed the development of viruses that are tumor-selective and armed with transgenes...
Source: Oral Oncology - October 15, 2009 Category: Cancer & Oncology Authors: Kengo Saito, Hiroshi Shirasawa, Naohisa Isegawa, Masashi Shiiba, Katsuhiro Uzawa, Hideki Tanzawa Tags: Reviews Source Type: journals

Expression of IFN-{beta} Enhances Both Efficacy and Safety of Oncolytic Vesicular Stomatitis Virus for Therapy of MesotheliomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Our preclinical and clinical trials using a replication-defective adenoviral vector expressing IFN-β have shown promising results for the treatment of malignant mesothelioma. Based on the hypotheses that a replication-competent vesicular stomatitis virus (VSV) oncolytic vector would transduce more tumor cells in vivo, that coexpression of the immunostimulatory IFN-β gene would enhance the immune-based effector mechanisms associated both with regression of mesotheliomas and with VSV-mediated virotherapy, and that virus-derived IFN-β would add further safety to the VSV platform, we tested the use of IFN-β...
Source: Cancer Research - October 1, 2009 Category: Cancer & Oncology Authors: Willmon, C. L., Saloura, V., Fridlender, Z. G., Wongthida, P., Diaz, R. M., Thompson, J., Kottke, T., Federspiel, M., Barber, G., Albelda, S. M., Vile, R. G. Tags: Experimental Therapeutics, Molecular Targets, and Chemical Biology Source Type: journals

Optimization of Virotherapy for Cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Several viruses preferentially infect and replicate in cancer cells by usurping pathways that are defective in the tumor cell population. Such viruses have a potential as oncolytic agents. The aim of tumor virotherapy is that after injection of the replicating virus, it propagates in the tumor cell population with amplification. As a result, the oncolytic virus spreads to eradicate the tumor. The outcome of tumor virotherapy is determined by population dynamics and different from standard cancer therapy. Several models have been developed that provided considerable insights on the potential therapeutic scenarios. Howev...
Source: Bulletin of Mathematical Biology - September 28, 2009 Category: Bioinformatics Authors: Biesecker M, Kimn JH, Lu H, Dingli D, Bajzer Z Tags: Bull Math Biol Source Type: journals

An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion. ZD55-IL-24 combined with ADM demonstrates improved killing effects against lung tumor xenograft. PMID: 19734998 [PubMed - as supplied by publisher] (Source: Acta Oncologica)
Source: Acta Oncologica - September 3, 2009 Category: Cancer & Oncology Authors: Zhong S, Yu D, Wang Y, Qiu S, Wu S, Liu X Tags: Acta Oncol Source Type: journals

Overexpression of Newcastle disease virus (NDV) V protein enhances NDV production kinetics in chicken embryo fibroblasts.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Newcastle disease virus (NDV) is not only one of the most economically important pathogen of poultry but also has a potential as anticancer virotherapy. The role of NDV V protein in virus-production kinetics was investigated using DF-1 cell-based production system. The presence of an anti-interferon (IFN)-alpha antibody resulted in enhanced NDV production kinetics in a dose-dependent manner by blocking binding of NDV-induced IFN to its receptor. To prepare DF-1 cell whose cellular IFN signaling is blocked efficiently, stable cell lines expressing either lentogenic or velogenic NDV V protein known as an IFN antagonist w...
Source: Applied Microbiology and Biotechnology - September 2, 2009 Category: Microbiology Authors: Jang J, Hong SH, Choi D, Choi KS, Kang S, Kim IH Tags: Appl Microbiol Biotechnol Source Type: journals

Targeted Radiotherapy for Prostate Cancer with an Oncolytic Adenovirus Coding for Human Sodium Iodide Symporter.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: These results suggest that oncolytic adenovirus-mediated targeted radiotherapy might be a potentially useful option for enhancing the efficacy or adenoviral virotherapy. (Clin Cancer Res 2009;15(17):5396-403). PMID: 19706820 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - August 24, 2009 Category: Cancer & Oncology Authors: Hakkarainen T, Rajecki M, Sarparanta M, Tenhunen M, Airaksinen AJ, Desmond RA, Kairemo K, Hemminki A Tags: Clin Cancer Res Source Type: journals

A chimeric adenovirus with an Ad 3 fiber knob modification augments glioma virotherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Malignant gliomas remain refractory to treatment despite advances in chemotherapy and surgical techniques. Viral vectors developed to treat gliomas have had low transduction capabilities, limiting their use. Gliomas over-express CD46, CD80, and CD86, all of which bind adenovirus serotype 3.To increase the infectivity and replication of oncolytic vectors in malignant brain tumors, we created a conditionally replicating adenovirus, CRAd-Survivin-5/3, which contains a survivin promoter-driving E1A and a chimeric fiber consisting of adenovirus serotype 3 knob.In vitro, this modified CRAd showed ten- to 100-fold increased cytot...
Source: The Journal of Gene Medicine - August 16, 2009 Category: Genetics & Stem Cells Authors: Suvobroto Nandi, Ilya V. Ulasov, Cleo E. Rolle, Yu Han, Maciej S. Lesniak Source Type: journals

Construction of a MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for gene therapy of breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: This construct may allow multimodal therapy, combining virotherapy with radioiodine therapy to be developed as a novel treatment for breast and other MUC1 overexpressing cancers. (Source: Breast Cancer Research)
Source: Breast Cancer Research - July 26, 2009 Category: Cancer & Oncology Authors: Miguel TrujilloMichael OnealJulia DavydovaElizabeth BergertMasato YamamotoJohn Morris Source Type: journals

Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer deaths in American males today. Novel and effective treatment such as gene therapy is greatly desired. The early viral based gene therapy uses tissue-nonspecific promoters, which causes unintended toxicity to other normal tissues. In this chapter, we will review the transcriptionally regulated gene therapy strategy for prostate cancer treatment. We will describe the development of transcriptionally regulated prostate cancer gene therapy in the following areas: (1) Comparison of different routes for best viral delivery to the ...
Source: Advanced Drug Delivery Reviews - June 27, 2009 Category: Drugs & Pharmacology Authors: Lu Y Tags: Adv Drug Deliv Rev Source Type: journals

Cancer cell death by design: Apoptosis, autophagy and glioma virotherapy.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Autophagy has been defined as a mechanism by which oncolytic adenoviruses mediate cell killing in some cancers, including malignant glioma. Until recently, however, adenovirus replication was regarded as a process that induced classical apoptosis in the infected cell. We have assessed the method of conditionally replicating adenovirus (CRAd) death in a model of malignant glioma, considering both autophagy and apoptosis as possible mechanisms of virally-induced cell death. Our initial investigations indicated that autophagy was the predominant system in CRAd-induced cell death in glioma. This appeared to be the case in ...
Source: Autophagy - June 27, 2009 Category: Cytology Authors: Tyler MA, Ulasov IV, Lesniak MS Tags: Autophagy Source Type: journals

Epithelial Phenotype Confers Resistance of Ovarian Cancer Cells to Oncolytic AdenovirusesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We studied the susceptibility of primary ovarian cancer cells to oncolytic adenoviruses. Using gene expression profiling of cancer cells either resistant or susceptible to viral oncolysis, we discovered that the epithelial phenotype of ovarian cancer represents a barrier to infection by commonly used oncolytic adenoviruses targeted to coxsackie-adenovirus receptor or CD46. Specifically, we found that these adenovirus receptors were trapped in tight junctions and not accessible for virus binding. Accessibility to viral receptors was critically linked to depolarization and the loss of tight and adherens junctions, both hallm...
Source: Cancer Research - June 15, 2009 Category: Cancer & Oncology Authors: Strauss, R., Sova, P., Liu, Y., Li, Z. Y., Tuve, S., Pritchard, D., Brinkkoetter, P., Moller, T., Wildner, O., Pesonen, S., Hemminki, A., Urban, N., Drescher, C., Lieber, A. Tags: Experimental Therapeutics, Molecular Targets, and Chemical Biology Source Type: journals

Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We examined the ability of genetically engineered HSV to infect and kill cells that express CD133, a putative marker of glioma progenitor cells (GPC), to determine if GPC have an inherent therapeutic resistance to HSV. Expression of CD133 and CD111 (nectin-1), the major entry molecule for HSV, was variable in six human glioma xenografts, at initial disaggregation and after tissue culture. Importantly, both CD133+ and CD133− populations of glioma cells expressed CD111 in similar relative proportions in five xenografts, and CD133+ and CD133− glioma cell subpopulations were equally sensitive to killing in vitro ...
Source: Journal of Neuro-Oncology - June 12, 2009 Category: Cancer & Oncology Tags: Journal of Neuro-Oncology Source Type: journals

An oncolytic adenovirus expressing herpes simplex virus-thymidine kinase for targeting cancer therapy: An in vitro evaluationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion An oncolytic adenovirus plus the HSV-TK/GCV suicide gene system resulted in a significant improvement in treatment efficacy and it may offer important considerations in the development and preclinical assessments of oncolytic virotherapy. Content Type Journal ArticleCategory Cancer Gene TherapyDOI 10.1007/s11670-009-0090-zAuthors Fei-qun Zheng, Peking University School of Oncology, Beijing Cancer Hospital & Institute Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Interventional therapy Beijing 100142 ChinaYin Xu, Anhui Medical University De...
Source: Chinese Journal of Cancer Research - June 12, 2009 Category: Cancer & Oncology Tags: Chinese Journal of Cancer Research Source Type: journals

[Microbiology] Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Oncolytic virotherapy exploits the ability of viruses to infect, replicate into, and kill tumor cells. Among the viruses that entered... (Source: Proceedings of the National Academy of Sciences)
Source: Proceedings of the National Academy of Sciences - June 2, 2009 Category: Science Authors: Menotti, L., Nicoletti, G., Gatta, V., Croci, S., Landuzzi, L., De Giovanni, C., Nanni, P., Lollini, P.-L., Campadelli-Fiume, G. Tags: Microbiology Source Type: journals

Targeted genetic and viral therapy for advanced head and neck cancers.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Head and neck cancers usually present with advanced disease and novel therapies are urgently needed. Genetic therapy aims at restoring malfunctioned tumor suppressor gene(s) or introducing proapoptotic genes. Oncolytic virotherapeutics induce multiple cycles of cancer-specific virus replication, followed by oncolysis, virus spreading and infection of adjacent cancer cells. Oncolytic viruses can also be armed to express therapeutic transgene(s). Recent advances in preclinical and clinical studies are revealing the potential of both therapeutic classes for advanced head and neck cancers, including the approval of two pro...
Source: Drug Discovery Today - May 31, 2009 Category: Drugs & Pharmacology Authors: Huang PI, Chang JF, Kirn DH, Liu TC Tags: Drug Discov Today Source Type: journals

Pharmacologic and Chemical Adjuvants in Tumor VirotherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Chemical Reviews, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). (Source: Chemical Reviews)
Source: Chemical Reviews - May 23, 2009 Category: Chemistry Tags: article Source Type: journals

Adenoviral virotherapy for malignant brain tumorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Expert Opinion on Biological Therapy , June 2009, Vol. 9, No. 6, Pages 737-747. (Source: Expert Opinion: Expert Opinion on Biological Therapy: Table of Contents)
Source: Expert Opinion: Expert Opinion on Biological Therapy: Table of Contents - May 20, 2009 Category: Drugs & Pharmacology Tags: article Source Type: journals

Drug-regulatable cancer cell death induced by BID under control of the tissue-specific, lung cancer-targeted TTS promoter systemEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Gene therapy and virotherapy are among the approaches currently being used to treat lung cancer. The success of cancer gene therapy depends on treatments where different types of tumors can be selectively targeted and destroyed without affecting normal cells and tissue. Previously, we described a promoter system (TTS) that we designed that is specifically targeted to lung cancer cells but which does not affect other types of cells including stem cells. In our study, we have enhanced the utility of the TTS system by inserting the pro-apoptotic gene BH3 domain interacting death agonist (Bid) into the TTS promoter system (TTS...
Source: International Journal of Cancer - May 17, 2009 Category: Cancer & Oncology Authors: Takuya Fukazawa, Yutaka Maeda, Junji Matsuoka, Noriaki Tanaka, Hirotoshi Tanaka, Mary L. Durbin, Yoshio Naomoto Source Type: journals

Advancements in adenoviral based virotherapy for ovarian cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Ovarian cancer is a leading gynecologic malignancy with relatively grim survival statistics. There is a significant need for the development of new treatment options for this malignancy. The development of virotherapy as a treatment option for ovarian cancer has the potential to improve patient survival. Adenoviruses have multiple advantages as vectors for virotherapy including a well-understood structure and the ability to infect cells easily. We will outline the advances in virotherapy in the treatment of ovarian cancer, with particular attention directed toward adenoviral vectors. PMID: 19422865 [PubMed - as sup...
Source: Advanced Drug Delivery Reviews - May 4, 2009 Category: Drugs & Pharmacology Authors: Matthews KS, Alvarez RD, Curiel DT Tags: Adv Drug Deliv Rev Source Type: journals

Human precision-cut liver tumor slices as a tumor patient-individual predictive test system for oncolytic measles vaccine viruses.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, the PCLS technology is suitable to perform a tumor-patient individualized preselection of oncolytic agents prior to clinical virotherapeutic applications. PMID: 19360338 [PubMed - in process] (Source: International Journal of Oncology)
Source: International Journal of Oncology - April 30, 2009 Category: Cancer & Oncology Authors: Zimmermann M, Armeanu S, Smirnow I, Kupka S, Wagner S, Wehrmann M, Rots MG, Groothuis GM, Weiss TS, Königsrainer A, Gregor M, Bitzer M, Lauer UM Tags: Int J Oncol Source Type: journals

Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myelomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In multiple myeloma, some of the neoplastic plasma cells are diffusely dispersed among the normal bone marrow cells (bone marrow resident), whereas others are located in discrete, well-vascularized solid tumors (plasmacytomas) that may originate in bone or soft tissue. Interactions between bone marrow-resident myeloma cells and bone marrow stromal cells (BMSCs) are important determinants of myeloma pathogenesis. However, little is known of the factors sustaining myeloma growth and cell viability at the centers of expanding plasmacytomas, where there are no BMSCs. Histologic sections of 22 plasmacytomas from myeloma patient...
Source: American Journal of Hematology - April 28, 2009 Category: Hematology Authors: Kah-Whye Peng, Ahmet Dogan, Julie Vrana, Chunsheng Liu, Hooi T. Ong, Shaji Kumar, Angela Dispenzieri, Allan B. Dietz, Stephen J. Russell Source Type: journals

Measles virotherapy in prostate cancer treatment: a novel antitumor approachEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Future Virology , May 2009, Vol. 4, No. 3, Pages 203-207. (Source: Future Virology)
Source: Future Virology - April 27, 2009 Category: Virology Tags: article Source Type: journals

The emergence of combinatorial strategies in the development of RNA oncolytic virus therapiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Oncolytic viruses (OVs) represent an exciting new biological approach to cancer therapy. In particular, RNA viruses have emerged as potent agents for oncolytic virotherapy because of their capacity to specifically target and destroy tumour cells while sparing normal cells and tissues. Several barriers remain in the development of OV therapy, including poor penetration into the tumour mass, inefficient virus replication in primary cancers, and tumour-specific resistance to OV-mediated killing. The combination of OVs with cytotoxic agents, such as small molecule inhibitors of signalling or immunomodulators, as well as stealt...
Source: Cellular Microbiology - April 20, 2009 Category: Microbiology Authors: Thi Lien-Anh Nguyen, Vanessa Fonseca Tumilasci, Diane Singhroy, Meztli Arguello, John Hiscott Source Type: journals

Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Live attenuated vaccine strain of measles virus (MV) has promising antitumor activity and is undergoing clinical testing in three different phase I cancer trials. The virus uses one of two receptors, CD46 which is ubiquitously expressed on all nucleated cells or CD150 which is expressed on immune cells, to infect cells. To minimize potential toxicity due to indiscriminate infection of normal cells, we have generated a fully retargeted MV that infects cells exclusively through the prostate-specific membrane antigen (PSMA) receptor, which is overexpressed on prostate cancer cells and tumor neovasculature.A single-chain antib...
Source: The Prostate - April 18, 2009 Category: Urology & Nephrology Authors: Chunsheng Liu, Kosei Hasegawa, Stephen J. Russell, Michel Sadelain, Kah-Whye Peng Source Type: journals

VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
rth, F Kühnel & S Kubicka (Source: Gene Therapy)
Source: Gene Therapy - April 16, 2009 Category: Genetics & Stem Cells Authors: P SchacheE GürlevikN StrüverN WollerN MalekL ZenderM MannsT WirthF KühnelS Kubicka Source Type: journals

Adenovirus-based virotherapy enabled by cellular YB-1 expression in vitro and in vivoEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Kaszubiak, H Lage & P S Holm (Source: Cancer Gene Therapy)
Source: Cancer Gene Therapy - April 10, 2009 Category: Cancer & Oncology Authors: E RognoniM WidmaierC HaczekK MantwillR HolzmüllerB GansbacherA KolkT SchusterR M SchmidD SaurA KaszubiakH LageP S Holm Source Type: journals

CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental gliomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
um & S A Kaliberov (Source: Cancer Gene Therapy)
Source: Cancer Gene Therapy - April 10, 2009 Category: Cancer & Oncology Authors: L N KaliberovaV KrendelchtchikovaD K HarmonC R StockardA S PetersenJ M MarkertG Y GillespieW E GrizzleD J BuchsbaumS A Kaliberov Source Type: journals

Telomerase-specific virotheranostics for human head and neck cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: These results illustrate the potential of telomerase-specific oncolytic viruses for a novel therapeutic and diagnostic approach, termed theranostics, for human SCCHN. PMID: 19318473 [PubMed - in process] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - April 1, 2009 Category: Cancer & Oncology Authors: Kurihara Y, Watanabe Y, Onimatsu H, Kojima T, Shirota T, Hatori M, Liu D, Kyo S, Mizuguchi H, Urata Y, Shintani S, Fujiwara T Tags: Clin Cancer Res Source Type: journals

Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We describe for the first time in an in vitro co-culture system that T lymphocytes can be loaded with Newcastle disease virus (NDV) in such a way that the virus load will be transferred to the tumor target cells upon contact of the T cells with tumor cells. The effectiveness of this NDV 'hitchhiking' on T cells can be influenced by the amount of virus, the ratio of T cells to tumor cells, the activation status of the T cells and by the virulence of the virus as shown by flow cytometry, quantitative real-time PCR and fluorescence microscopy. In a tumor neutralization assay in vitro, monolayers of human tumor cells could be ...
Source: International Journal of Oncology - March 20, 2009 Category: Cancer & Oncology Authors: Pfirschke C, Schirrmacher V Tags: Int J Oncol Source Type: journals

A novel recombinant vaccinia virus expressing the human norepinephrine transporter retains oncolytic potential and facilitates deep tissue imaging.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Noninvasive and repetitive monitoring of a virus in target tissues and/or specific organs of the body is highly desirable for the development of safe and efficient cancer virotherapeutics. We have previously shown that the oncolytic vaccinia virus GLV-1h68 can target and eradicate human tumors in mice and that its therapeutic effects can be monitored using optical imaging. Here, we report on the development of a novel recombinant vaccinia virus (VACV) GLV-1h99, a derivative of GLV-1h68, which was constructed to carry the human norepinephrine transporter gene (hNET) under the VACV synthetic early promoter placed at the ...
Source: Molecular Medicine - March 14, 2009 Category: Molecular Biology Authors: Chen N, Zhang Q, Yu YA, Stritzker J, Brader P, Schirbel A, Samnick S, Serganova I, Blasberg R, Fong Y, Szalay AA Tags: Mol Med Source Type: journals

Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivoEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
p; M S Lesniak (Source: British Journal of Cancer AOP)
Source: British Journal of Cancer AOP - March 10, 2009 Category: Cancer & Oncology Authors: I V UlasovA M SonabendS NandiA KhramtsovY HanM S Lesniak Source Type: journals

Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion:This study showed that ZD55-IL-24 conjugated with cisplatin exhibited a remarkably increased cytotoxic and apoptosis-inducing effect in cancer cells and significantly reduced the toxicity in normal cells through the use of a reduced dose.Acta Pharmacologica Sinica advance online publication, 9th March 2009; doi: 10.1038/aps.2009.16. PMID: 19270721 [PubMed - as supplied by publisher] (Source: Acta Pharmacologica Sinica)
Source: Acta Pharmacologica Sinica - March 9, 2009 Category: Drugs & Pharmacology Authors: Wu YM, Zhang KJ, Yue XT, Wang YQ, Yang Y, Li GC, Li N, Wang YG Tags: Acta Pharmacol Sin Source Type: journals

Potent antitumor activity of double-regulated oncolytic adenovirus-mediated ST13 for colorectal cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Following targeted gene virotherapy, the suppression of tumorigenicity 13 (ST13) gene was inserted into the double-regulated oncolytic adenovirus SG500 to ensure more safety and potent antitumor activity against colorectal cancer in vitro and in vivo. We generated the ST13-expressing oncolytic adenovirus SG500-ST13, with which colorectal carcinoma cell lines SW620 and HCT116, and the lung fibroblast cell line WI38, were infected. Crystal violet staining was carried out to detect the cytopathic effect in cells, and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method was used to assay cell viability. The ...
Source: Cancer Science - March 1, 2009 Category: Cancer & Oncology Authors: De Bin Yu, Su Yang Zhong, Min Yang, Yi Gang Wang, Qi Jun Qian, Shu Zheng, Xin Yuan Liu Source Type: journals

Measles Virus May Be Effective Prostate Cancer TreatmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A new study appearing in The Prostate has found that certain measles virus vaccine strain derivatives, including a strain known as MV-CEA, may prove to be an effective treatment for patients with advanced prostate cancer. The findings show that this type of treatment, called virotherapy, can effectively infect, replicate in and kill prostate cancer cells. Prostate cancer is a leading cause death among males in the western world. It is currently the second most common cause of cancer-related deaths among American men with 186,320 new cases and 28,660 deaths expected to be recorded in 2008. A sizeable proportion of these pat...
Source: Cancercompass News: Prostate Cancer - February 20, 2009 Category: Cancer & Oncology Source Type: news

Combination of oncolytic adenoviral therapy with chemotherapy for enhanced breast cancer cell killing.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we investigated a combination treatment of breast cancer cells with Ad5-4-RGD and Docetaxel, a microtubule-stabilizing taxane that is being used in the clinic for the treatment of breast and prostate cancers and small cell carcinoma of the lung. Our results indicate a synergistic effect between Docetaxel and Ad5-24-RGD in breast cancer cell killing at a lower dose than either agent alone. These results suggest that viral replication was not inhibited by this chemotherapy treatment and that chemotherapy could reduce the amount of viral particles needed to help eradicate the tumor. Administration of lower vira...
Source: Cancer Research - February 19, 2009 Category: Cancer & Oncology Authors: Stoff-Khalili, M., Nedeljkovic-Kurepa, A, Jung, J., Glover, B., Wappenschmidt, B, Rhiem, K, Bosse, K, Mallmann, P, Curiel, D., Schmutzler, R., Mathis, M. Tags: Novel Targets and Targeted Agents Source Type: journals

Telomerase-specific virotherapy for human squamous cell carcinomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Expert Opinion on Biological Therapy , March 2009, Vol. 9, No. 3, Pages 321-329. (Source: Expert Opinion: Expert Opinion on Biological Therapy: Table of Contents)
Source: Expert Opinion: Expert Opinion on Biological Therapy: Table of Contents - February 13, 2009 Category: Drugs & Pharmacology Tags: article Source Type: journals

Antitumoral Immune Response by Recruitment and Expansion of Dendritic Cells in Tumors Infected with Telomerase-Dependent Oncolytic VirusesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Virotherapy can potentially be used to induce tumor-specific immune responses and to overcome tumor-mediated tolerance mechanisms because apoptotic tumor cells are exposed together with viral danger signals during oncolysis. However, insufficient numbers of dendritic cells (DC) present at the site of oncolysis can limit a tumor-specific immune response and the resulting therapeutic benefit. We investigated MHC class I peptide–specific immune responses against model antigens ovalbumin (OVA) and hemagglutinin (HA) in mouse tumor models that support efficient replication of the oncolytic adenovirus hTert-Ad. Virotherapy...
Source: Cancer Research - February 12, 2009 Category: Cancer & Oncology Authors: Ramakrishna, E., Woller, N., Mundt, B., Knocke, S., Gurlevik, E., Saborowski, M., Malek, N., Manns, M. P., Wirth, T., Kuhnel, F., Kubicka, S. Tags: Experimental Therapeutics, Molecular Targets, and Chemical Biology Source Type: journals

Armed replicating adenoviruses for cancer virotherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
ouglas (Source: Cancer Gene Therapy)
Source: Cancer Gene Therapy - February 8, 2009 Category: Cancer & Oncology Authors: J J CodyJ T Douglas Source Type: journals

Antitumoral Immune Response by Recruitment and Expansion of Dendritic Cells in Tumors Infected with Telomerase-Dependent Oncolytic Viruses.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Virotherapy can potentially be used to induce tumor-specific immune responses and to overcome tumor-mediated tolerance mechanisms because apoptotic tumor cells are exposed together with viral danger signals during oncolysis. However, insufficient numbers of dendritic cells (DC) present at the site of oncolysis can limit a tumor-specific immune response and the resulting therapeutic benefit. We investigated MHC class I peptide-specific immune responses against model antigens ovalbumin (OVA) and hemagglutinin (HA) in mouse tumor models that support efficient replication of the oncolytic adenovirus hTert-Ad. Virotherapy r...
Source: Cell Research - February 3, 2009 Category: Cytology Authors: Ramakrishna E, Woller N, Mundt B, Knocke S, Gürlevik E, Saborowski M, Malek N, Manns MP, Wirth T, Kühnel F, Kubicka S Tags: Cancer Res Source Type: journals

A multiscale mathematical model for oncolytic virotherapy.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
One of the most promising strategies to treat cancer is attacking it with viruses. Oncolytic viruses can kill tumor cells specifically or induce anticancer immune response. A multiscale model for virotherapy of cancer is investigated through simulations. It was found that, for intratumoral virus administration, a solid tumor can be completely eradicated or keep growing after a transient remission. Furthermore, the model reveals undamped oscillatory dynamics of tumor cells and virus populations, which demands new in vivo and in vitro quantitative experiments aiming to detect this oscillatory response. The conditions for...
Source: Cell Research - January 31, 2009 Category: Cytology Authors: Paiva LR, Binny C, Ferreira SC, Martins ML Tags: Cancer Res Source Type: journals

A Multiscale Mathematical Model for Oncolytic VirotherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
One of the most promising strategies to treat cancer is attacking it with viruses. Oncolytic viruses can kill tumor cells specifically or induce anticancer immune response. A multiscale model for virotherapy of cancer is investigated through simulations. It was found that, for intratumoral virus administration, a solid tumor can be completely eradicated or keep growing after a transient remission. Furthermore, the model reveals undamped oscillatory dynamics of tumor cells and virus populations, which demands new in vivo and in vitro quantitative experiments aiming to detect this oscillatory response. The conditions for whi...
Source: Cancer Research - January 29, 2009 Category: Cancer & Oncology Authors: Paiva, L. R., Binny, C., Ferreira, S. C., Martins, M. L. Tags: Systems Biology and Emerging Technologies Source Type: journals

Prostate Cancer: Measles Virus May Be Effective TreatmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A new study appearing in The Prostate has found that certain measles virus vaccine strain derivatives, including a strain known as MV-CEA, may prove to be an effective treatment for patients with advanced prostate cancer. The findings show that this type of treatment, called virotherapy, can effectively infect, replicate in and kill prostate cancer cells. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 22, 2009 Category: Consumer Health News Tags: Prostate / Prostate Cancer Source Type: news

Measles Virus May Be Effective Prostate Cancer TreatmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A new study appearing in The Prostate has found that certain measles virus vaccine strain derivatives, including a strain known as MV-CEA, may prove to be an effective treatment for patients with advanced prostate cancer. The findings show that this type of treatment, called virotherapy, can effectively infect, replicate in and kill prostate cancer cells. (Source: Huliq Health News)
Source: Huliq Health News - January 22, 2009 Category: Consumer Health News Authors: harminka Tags: Health men & #039;s health prostate cancer prostate cancer treatment Source Type: news

Coagulation Factors Determine Tumor Transduction In VivoEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Human Gene Therapy , Vol. 0, No. 0: 1-6. A critical obstacle for efficient gene therapy and virotherapy of cancer with adenoviral vectors and oncolytic adenoviruses is to target tumor cells in vivo. Recent reports indicate that, contrary to the natural airborne infection of epithelial cells with ... (Source: Human Gene Therapy)
Source: Human Gene Therapy - November 29, 2008 Category: Genetics & Stem Cells Tags: article Source Type: journals

Inhibition of renal cancer cell growth by oncolytic adenovirus armed short hairpin RNA targeting hTERT gene.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we constructed a novel oncolytic adenovirus-based shRNA expression system, ZD55-hTERT, and to explore ZD55-hTERT-mediated RNAi for hTERT gene silencing. Our results showed that ZD55-hTERT could induce silencing of hTERT gene effectively, allow for efficient tumor-specific viral replication and induce the apoptosis of tumor cells effectively in vitro and in nude mice. We conclude that combining shRNA gene therapy and oncolytic virotherapy can enhance antitumor efficacy as a result of synergism between CRAd oncolysis and shRNA antitumor responses. PMID: 19029834 [PubMed - as supplied by publisher] (Source:...
Source: Cancer Biology and Therapy - November 27, 2008 Category: Cancer & Oncology Authors: Zheng JN, Pei DS, Sun FH, Zhang BF, Liu XY, Gu JF, Liu YH, Hu XL, Mao LJ, Wen RM, Liu JJ, Li W Tags: Cancer Biol Ther Source Type: journals

Oncolytic virotherapy for advanced liver tumoursEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Introduction Pre-clinical studies Clinical studies Challenges for the use of virotherapy agents in liver tumour treatment Future directions Primary and metastatic neoplasms of the liver account for more than a million deaths per year worldwide. Despite decades of research, effective novel therapies for these cancers are urgently needed. Oncolytic virotherapeutics represent a novel class of pharmacophore that holds promise for the treatment of hepatic neoplasms. Cancer-specific replication is followed by oncolysis, virus spreading and infection of adjacent cancer cells. This process is then repeated. Virotherapeutics target...
Source: Journal of Cellular and Molecular Medicine - October 22, 2008 Category: Molecular Biology Authors: Ju-Fang Chang, Pei-Jer Chen, Daniel Y. Sze, Tony Reid, David Bartlett, David H. Kirn, Ta-Chiang Liu Tags: REVIEWS Source Type: journals

Oncolytic Semliki Forest Virus Vector as a Novel Candidate against Unresectable OsteosarcomaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Oncolytic viruses are a promising tool for treatment of cancer. We studied an oncolytic Semliki Forest virus (SFV) vector, VA7, carrying the enhanced green fluorescent protein gene (EGFP), as a novel virotherapy candidate against unresectable osteosarcoma. The efficiency and characteristics of the VA7-EGFP treatment were compared with a widely studied oncolytic adenovirus, Ad524, both in vitro and in vivo. VA7-EGFP resulted in more rapid oncolysis and was more efficient at low multiplicities of infection (MOI) when compared with Ad524 in vitro. Yet, in MG-63 cells, a subpopulation resistant to the VA7-EGFP vector emerged. ...
Source: Cancer Research - October 15, 2008 Category: Cancer & Oncology Authors: Ketola, A., Hinkkanen, A., Yongabi, F., Furu, P., Maatta, A.-M., Liimatainen, T., Pirinen, R., Bjorn, M., Hakkarainen, T., Makinen, K., Wahlfors, J., Pellinen, R. Tags: Experimental Therapeutics, Molecular Targets, and Chemical Biology Source Type: journals

Bevacizumab Increases Viral Distribution in Human Anaplastic Thyroid Carcinoma Xenografts and Enhances the Effects of E1A-Defective Adenovirus dl922-947.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: Our data showed that dl922-947 had a higher oncolytic activity compared with dl1520 in anaplastic thyroid carcinoma cell lines and might represent a better option for virotherapy of anaplastic thyroid carcinoma. Moreover, bevacizumab increased the oncolytic effects of dl922-947 by enhancing viral distribution in tumors. The results described herein encourage the use of the dl922-947 virus in combination with bevacizumab. PMID: 18927290 [PubMed - in process] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 15, 2008 Category: Cancer & Oncology Authors: Libertini S, Iacuzzo I, Perruolo G, Scala S, Ieranò C, Franco R, Hallden G, Portella G Tags: Clin Cancer Res Source Type: journals